Skip to content
Friday 24 July 2026London --:--Frankfurt --:--Zurich --:--
NewslettersSearchEN · DE
City PM

European business, markets and politics

FTSE 100
10,675.91
+0.35%
DAX
24,966.68
+0.82%
CAC 40
8,332.87
+0.41%
STOXX 50
6,256.70
+0.75%
  • Europe
  • Markets
  • Business
  • Economy
  • Technology
  • Politics
  • Opinion
More
GermanyFranceBankingAIEnergyFintechPropertyCapital Markets
  • Germany
  • France
  • Europe
  • Markets
  • Business
  • Economy
  • Technology
  • Politics
  • Opinion
  • DE
Wednesday 16 December 2020 11:17 am

New biotech rapid-testing facility to help London ‘return to normality’

By: Luke Harrison

Add as a preferred source on Google

A biotech company, Biogroup is launching a new rapid-testing facility in London, which will boost testing capacity in the capital by 100,000 tests a week.

Biogroup UK is setting-up an RT-PCR (RealTime Reverse Transcription Polymerase Chain Reaction) test service, initially via two pop-up testing centres in Marylebone and Notting Hill to detect the presence of the virus.

The swabs will then be sent to a MegaLab in Shepherds Bush, that will process results within 24-hours.

The biotech firm boasts an impressive efficiency record on its testing services, identifying 99 per cent of infections within this 24-hour period.

Dr. Astrid Gouillard, chairman of Biogroup UK said: “Testing is central in the fight to control the spread of the virus. It allows those infected to be isolated to prevent or at least slow down the number of new infections. It is also key in the future management of the pandemic, establishing how much the virus has spread across the broader population and understanding the level of immunity across the UK.”

“The additional capacity from private labs for both corporates and consumers will considerably help people return to normality by reducing self-isolation and re-opening the country to business travel,” he concluded.

Despite the government announcing today that 137,000 people got the Covid vaccine within the first week, the news that London has moved into Tier 3 shows that we are still some way from wide-spread vaccinations and any sense of normality.

In the mean time, effective testing facilities like the one being lunched by Biogroup UK hold the key to keeping down infection rates in the capital and the rest the UK.

Read more

Patent cliff fuels Novartis’ $1.5bn swoop for London biotech

Hikma produces generic drugs

Share this article

  • Facebook
  • X
  • LinkedIn
  • WhatsApp
  • Email

Similarly tagged content:

Sections

  • News

Categories

  • Business
  • Tech

Related Topics

  • Coronavirus

Trending Articles

  • BT braces for loss of 800,000 customers as it banks on fibre to keep turnaround ‘on track’

  • Regulator flags BDO’s ‘unacceptable’ audit issues for fifth year in a row 

  • Tax rises ‘guaranteed’ as Healey faces £22bn black hole from Burnham spending plans

  • ‘We are going to run out’: Mitie marks eleventh mega takeover of 2026

  • Scotch whisky sales are falling, but what’s really behind the decline?

More from City PM

  • Patent cliff fuels Novartis’ $1.5bn swoop for London biotech

    Healthcare
    Hikma produces generic drugs
  • CG Semi Commences Commercial Production at Its G1 OSAT Facility in Sanand, Gujarat

    Business Wire
  • Rehlko Announces €12 Million Expansion of Power Control & Distribution Manufacturing Facility in Cholet, France

    Business Wire
  • RS2 Financial Services GmbH Selected to Participate in ECB Digital Euro Pilot

    Business Wire
  • Nscale taps lenders for $900m to fuel AI data centre splurge

    Tech
    AI data center with rows of servers and cooling systems, showcasing advanced technology and infrastructure innovation
  • London Stock Exchange unveils ‘LSE24’ round-the-clock trading venue

    Markets
    Given no article content, categories, or tags, and a generic filename, I cannot generate a specific alt text. I need more ...
  • Echodyne Opens New Manufacturing Facility to Meet Surging Global Demand for Advanced MESA® Radar

    Business Wire
  • Dompé Doses First Patient in Phase 3 Study of Cenegermin-bkbj in NAION

    Business Wire
CityPM

Independent European business, markets and political news for decision-makers.

Morning Briefing

Europe

  • Germany
  • France
  • Europe
  • UK & Ireland

Business

  • Markets
  • Banking
  • Technology
  • Energy
  • Property
  • Fintech

Editorial

  • Opinion
  • Editorial Policy
  • Corrections
  • Contact

Company

  • About City PM
  • Privacy Policy
  • Terms of Use
  • Cookie Policy
© 2026 City PM Ltd · Published by CityPM Media, Bahnhofstrasse 65, 8001 Zürich, Switzerland
Privacy · Terms · Cookies · Facebook